Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4% | 19% | 0% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 85.2% | 79.6% | 85.5% | 84.2% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 14.9% | 12% | 2% | 9.5% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 0.8% | -2.7% | -15.3% | -8.5% |
| EPS Diluted | 0 | -0.012 | -0.061 | -0.034 |
| % Growth | 100% | 80% | -76.4% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |